Banque Pictet & Cie SA Has $27.86 Million Stake in Gilead Sciences, Inc. $GILD

Banque Pictet & Cie SA increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 168.8% in the 4th quarter, HoldingsChannel reports. The firm owned 227,007 shares of the biopharmaceutical company’s stock after acquiring an additional 142,543 shares during the period. Banque Pictet & Cie SA’s holdings in Gilead Sciences were worth $27,863,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in GILD. Csenge Advisory Group raised its stake in shares of Gilead Sciences by 319.0% in the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after purchasing an additional 16,288 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its holdings in Gilead Sciences by 52.1% during the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock worth $8,713,000 after acquiring an additional 26,882 shares during the last quarter. Cookson Peirce & Co. Inc. boosted its holdings in Gilead Sciences by 249.1% during the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock worth $1,115,000 after acquiring an additional 7,168 shares during the last quarter. Railway Pension Investments Ltd grew its stake in shares of Gilead Sciences by 3.1% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock worth $157,139,000 after acquiring an additional 42,200 shares in the last quarter. Finally, TriaGen Wealth Management LLC bought a new stake in shares of Gilead Sciences in the 3rd quarter worth $1,274,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $140.30 on Thursday. The firm has a market capitalization of $174.14 billion, a price-to-earnings ratio of 20.72, a P/E/G ratio of 1.83 and a beta of 0.37. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29. The stock has a fifty day moving average of $144.85 and a 200 day moving average of $129.14. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company’s revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the firm posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were issued a dividend of $0.82 per share. The ex-dividend date of this dividend was Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.3%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is presently 48.45%.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $144.23, for a total value of $432,690.00. Following the completion of the transaction, the insider directly owned 131,779 shares in the company, valued at approximately $19,006,485.17. The trade was a 2.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $144.23, for a total value of $432,690.00. Following the completion of the transaction, the chief financial officer directly owned 179,191 shares in the company, valued at approximately $25,844,717.93. This represents a 1.65% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 299,280 shares of company stock valued at $42,820,550. 0.27% of the stock is currently owned by insiders.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Ouro Medicines and struck a binding collaboration with Galapagos to advance T‑cell engager programs for autoimmune diseases — a clear push to expand its pipeline into potentially high‑value biologics and diversify beyond core antiviral franchises, which supports longer‑term growth expectations. Gilead Expands Autoimmune Ambitions With Ouro Deal And Galapagos Collaboration
• Positive Sentiment: RBC noted decent patient persistence for Yeztugo (HIV prevention), indicating commercial uptake is intact even if market expansion is limited — positive for ongoing revenue stability from Gilead’s HIV portfolio. Gilead Sciences Shows Solid Early Yeztugo Persistence but Limited Market Expansion, RBC Says
• Neutral Sentiment: Analysts expect single‑digit EPS growth for Q1 2026 — modest growth that keeps expectations muted vs. high‑growth peers but aligns with Gilead’s guidance and stable cash generation. This sets tempered near‑term performance expectations. Gilead Sciences’s Q1 2026 Earnings: What to Expect
• Neutral Sentiment: Market roundups and earnings/transcript coverage show Gilead’s stock has risen in recent sessions but still lagged broader indices — reflecting investor caution despite positive headlines. These pieces mainly summarize momentum rather than introduce new catalysts. Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing
• Neutral Sentiment: General investor commentary listing Gilead as an attractive dividend/ income name may support demand from income investors but is not an immediate catalyst for a large re‑rating. Markets Haven’t Changed. These 2 Cheap Dividends Still Rule
• Negative Sentiment: Gilead extended the tender offer for Arcellx at $115 plus a $5 CVR — the extension signals the deal hasn’t closed and increases short‑term uncertainty (and potential near‑term cash outflow). Investors may view extensions as a risk that the acquisition will be more costly, contested, or delayed. Gilead Extends Tender Offer to Acquire Arcellx

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Sanford C. Bernstein reiterated an “outperform” rating and issued a $160.00 price objective on shares of Gilead Sciences in a research note on Wednesday, February 11th. Truist Financial lifted their price target on shares of Gilead Sciences from $145.00 to $152.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Wall Street Zen upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 14th. UBS Group upped their price target on Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, Cantor Fitzgerald increased their price target on Gilead Sciences from $135.00 to $155.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $157.62.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.